Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes
Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes
复制标题
DOI：
10.1038/aja.2013.79
复制
发表时间：
2013-11-01
影响因子：
2.9
通讯作者：
Sun, Ying-Hao
中科院分区：
文献类型：
--
作者：
Cao, Zhi;Wang, Yang;Sun, Ying-Hao
转氨酶4已显示增强前列腺癌细胞的各种生物学特性，例如，细胞-基质粘附、侵袭性和上皮-间质转化。本研究的目的是研究转谷氨酰胺酶4表达与前列腺癌的既定特征和生化复发之间的关系。在组织微阵列上进行转氨酶4免疫染色。通过基于染色强度和程度的评分方法评价转氨酶4的表达。临床和病理信息通过查阅病历获得。通过查阅我科的住院病历和前列腺癌数据库以及联系患者或家属获得随访数据。然后，我们比较了前列腺癌组织和癌旁组织之间的转氨酶4表达水平，并评估了转氨酶4表达与前列腺癌的临床参数和生化复发的相关性。结果表明，肿瘤组织中转氨酶4的表达显著高于癌旁组织（P < 0.001），且与Gleason评分（P < 0.001）和前列腺特异性抗原（P=0.005）呈正相关。在单因素分析中，转氨酶4过表达的患者术后生化无复发生存期较短（P=0.042），但在多因素分析中没有（P=0.139），这表明转氨酶4可能是前列腺癌生化复发的潜在预测因子。
Transglutaminase 4 has been shown to enhance various biological properties of prostate cancer cells, e.g., cell-matrix adhesion, invasiveness and the epithelial-mesenchymal transition. The objectives of this study were to investigate the associations between transglutaminase 4 expression and the established features and biochemical recurrence of prostate cancer. Transglutaminase 4 immunostaining was performed on a tissue microarray. The expression of transglutaminase 4 was evaluated by a scoring method based on the intensity and extent of staining. The clinical and pathological information was obtained through a review of medical records. Follow-up data were obtained by consulting the hospital medical records and the prostate cancer database of our department and by contacting patients or family members. We then compared the transglutaminase 4 expression levels between the prostate cancer tissues and the paracarcinoma tissues and evaluated the correlation of transglutaminase 4 expression with the clinical parameters and biochemical recurrence of prostate cancer. Our results indicated that the transglutaminase 4 staining was significantly higher in tumour tissue than in paracarcinoma tissue (P < 0.001) and was positively associated with higher Gleason score (P < 0.001) and higher prostate-specific antigen level (P=0.005). Patients with transglutaminase 4 overexpression experienced shorter biochemical recurrence-free survival after surgery (P=0.042) in the univariate analysis but not in the multivariate analysis (P=0.139), which indicated that transglutaminase 4 may serve as a potential predictor of biochemical recurrence of prostate cancer.